Q-omics provides the consensus-scored THAP12P3 profile across patient tissues and cancer cell-line models. THAP12P3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, THAP12P3 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, THAP12P3 RNA expression shows 12,304 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LUAD, and GBM as cancer lineages where THAP12P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THAP12P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THAP12P3 survival associations across molecular data types. THAP12P3 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THAP12P3 RNA expression–survival associations across cancer types. High THAP12P3 expression shows unfavorable associations in BRCA, KIRC, LGG and LUSC, but favorable associations in CESC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for THAP12P3 RNA expression.
This table summarizes THAP12P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for THAP12P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THAP12P3 shows lower tumor expression in KIRP and higher tumor expression in LUAD, BLCA, BRCA, LIHC and PAAD. The LUAD box plot shows higher THAP12P3 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p < 0.001).
This table shows molecular features associated with THAP12P3 in patient tissues and cancer cell lines. In patient samples, THAP12P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
